TNFSF11 and Fabry disease: Using a constitutive rGαsR201C model, Palmisano et al. demonstrated that RANKL inhibition in young mice prevented the development of additional lesions.7 A phase 2 trial in children investigating the effect of denosumab on FD lesion progression is ongoing (NCT05419050).